SCHEMBL23975996

SCHEMBL23975996

COc1cccc(N2CCCN(I)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.58
MAPT P10636 5/20 0.57
NPC1 O15118 3/20 0.57
KCNH2 Q12809 2/20 0.56
DRD2 P14416 1/20 0.56
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TSHR P16473 2/20 0.51
KDM4E B2RXH2 2/20 0.51
RAB9A P51151 2/20 0.49
DHFR P00374 1/20 0.48
GFER P55789 1/20 0.47
QSOX1 O00391 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23675047 0.88 ADRB1 (0.71) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL3051915 0.85 ADRB1 (0.71) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL30255158 0.85 ADRB1 (0.71) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL11074672 0.85 ADRB1 (0.76) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL30180110 0.83 ADRB1 (0.69) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL3035322 0.83 ADRB1 (0.69) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL23657330 0.83 KCNH2 (0.61) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL19212406 0.80 ADRB1 (0.69) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL25917171 0.79 ADRB1 (0.55) ADRB1MAPTNPC1KCNH2DRD2
SCHEMBL25923493 0.79 DRD2 (0.69) ADRB1MAPTNPC1KCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed